Development of an efficient, robust MS-based platform for early detection of acute kidney injury

开发高效、稳健的基于 MS 的平台，用于早期检测急性肾损伤

• 批准号: G1000791/1
• 负责人: Harald Mischak
• 金额: $ 99.93万
• 依托单位: University of Glasgow
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1000791%2F1
• 关键词: Development; efficient; robust; MS; based

Acute Kidney Injury (AKI) as a severe complication in hospitalized patients, a life-threatening complication that still has a high mortality. In addition, AKI is associated with high costs for intensive and prolongued treatment. To date, no early detection of AKI is possible. However, early detection is essential to initiate appropriate treatment, thereby preventing development of disease, or at least reducing the severity. Such an appproach would reduce mortality, and also costs. The proposal aims at developing a technology platform that enables early detection of AKI, based on specific proteins an peptides in urine, so-called biomarkers. These biomarkers have already been identified. For their efficient clinical application a plattform that allows accurate and fast analysis has to be developed, this development is the scope of the project. Upon successful completion of the project, a robust technology will be available that enables early detection of AKI, hence initiation of appropriate early therapeutic measures. We anticipate that as a result of this project, mortality due to AKI can be significantly decreased, and costs can be reduced.

急性肾损伤（AKI）作为住院患者的严重并发症，是一种危及生命的并发症，死亡率仍然很高。此外，AKI 还与强化和长期治疗的高成本相关。迄今为止，尚无法早期检测 AKI。然而，早期检测对于开始适当的治疗至关重要，从而防止疾病的发展，或至少减轻其严重程度。这种方法将降低死亡率和成本。该提案旨在开发一个技术平台，基于尿液中的特定蛋白质和肽（即所谓的生物标志物），能够早期检测 AKI。这些生物标志物已经被识别。为了实现高效的临床应用，必须开发一个允许准确、快速分析的平台，这一开发是该项目的范围。该项目成功完成后，将提供一项强大的技术，能够及早发现 AKI，从而启动适当的早期治疗措施。我们预计，该项目的结果将显着降低 AKI 导致的死亡率，并降低成本。